Aerie Pharmaceuticals Competitors and Similar CompaniesClear all
Aerie Pharmaceuticals's competitors and similar companies include Sorrento Therapeutics, Catalyst Pharmaceuticals, scPharmaceuticals and Olainfarm.
 Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  scPharmaceuticals scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. |  Olainfarm Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia. | |
Founding Date | Founding Date 2005 | Founding Date 2006 | Founding Date 2002 | Founding Date 2014 | Founding Date 1972 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations San Diego, US HQ San Diego, US | Locations Coral Gables, US HQ | Locations Burlington, US HQ | Locations Olaine, LV HQ |
Employees | Employees 3808% increase | Employees 31019% decrease | Employees 7649% increase | Employees 96256% increase | Employees 2,191 |
Valuation ($) | Valuation ($) 722.2 m | Valuation ($) 1.5 m | Valuation ($) 2.6 b | Valuation ($) 221.6 m | Valuation ($) 150.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $491.7m (FY, 2024) | Revenue (est.) $36.3m (FY, 2024) | Revenue (est.) €122.2m (FY, 2020) |
Cost of goods | Cost of goods $26.8m (FY, 2021) | Cost of goods N/A | Cost of goods $68.8m (FY, 2024) | Cost of goods $11.4m (FY, 2024) | Cost of goods €44.5m (FY, 2020) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $422.9m (FY, 2024) | Gross profit $25m (FY, 2024) | Gross profit €80.1m (FY, 2020) |
Net income | Net income ($74.8m) (FY, 2021) | Net income ($577.8m) (FY, 2022) | Net income $163.9m (FY, 2024) | Net income ($85.1m) (FY, 2024) | Net income €9.5m (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised $ 388.6m | Total funding raised $ 42.6m | Total funding raised N/A | Total funding raised $ 62.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyCatalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View companyscPharmaceuticals
HQ
Burlington, US
Employees
96
scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.
View companyOlainfarm
HQ
Olaine, LV
Employees
2,191
Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia.
View company